Clinical Cancer Research, Vol 4, Issue 10 2503-2509, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Enhanced growth inhibition and differentiation of fluorodeoxyuridine-treated human colon carcinoma cells by phenylbutyrate

Y Huang and S Waxman
Department of Medicine, Mount Sinai Medical Center, New York, New York 10029, USA.

The effect of phenylbutyrate (PB), a nontoxic differentiation inducer, in human colon carcinoma cell lines treated with 5-fluorodeoxyuridine (FUdR) was evaluated. Two HT-29 human colon carcinoma subclones (U4 well differentiated and U9 poorly differentiated) were equally growth inhibited by 16 h of FUdR (0.2 microM) treatment but recovered cell growth in 3-6 days after the removal of FUdR. PB as a single agent had minimal effect on cell growth, but after FUdR treatment, PB inhibited cell growth for 12 days. The inhibition of cell growth in FUdR-treated cells by PB was more sustained in U4 than U9 cells and was associated with an increased and sustained expression of p21waf1 protein, secretion of transforming growth factor beta1, mediators of p53-dependent or -independent G1 cell cycle arrest, and an increase in the alkaline phosphatase activity as well, considered a marker of differentiation in colon carcinoma cells. These effects of PB were seen only in FUdR-pretreated cells because PB alone had minimal effect on the expression of these genes. The sequential use of FUdR followed by PB in patients with colon carcinoma should be explored because two subclones of HT29, irrespective of their state of differentiation, respond to this clinically achievable regimen.

This article has been cited by other articles:

				M. R. Acharya, A. Sparreboom, J. Venitz, and W. D. Figg Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review Mol. Pharmacol., October 1, 2005; 68(4): 917 - 932. [Abstract] [Full Text] [PDF]

				K. N. Bhalla Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies J. Clin. Oncol., June 10, 2005; 23(17): 3971 - 3993. [Abstract] [Full Text] [PDF]

				X.-N. Li, S. Parikh, Q. Shu, H.-L. Jung, C.-W. Chow, L. Perlaky, H.-C. E. Leung, J. Su, S. Blaney, and C. C. Lau Phenylbutyrate and Phenylacetate Induce Differentiation and Inhibit Proliferation of Human Medulloblastoma Cells Clin. Cancer Res., February 1, 2004; 10(3): 1150 - 1159. [Abstract] [Full Text] [PDF]

				D. A. Brown, R. L. Ward, P. Buckhaults, T. Liu, K. E. Romans, N. J. Hawkins, A. R. Bauskin, K. W. Kinzler, B. Vogelstein, and S. N. Breit MIC-1 Serum Level and Genotype: Associations with Progress and Prognosis of Colorectal Carcinoma Clin. Cancer Res., July 1, 2003; 9(7): 2642 - 2650. [Abstract] [Full Text] [PDF]

				S. A. McGrath-Morrow and J. L. Stahl G1 Phase Growth Arrest and Induction of p21Waf1/Cip1/Sdi1 in IB3-1 Cells Treated with 4-Sodium Phenylbutyrate J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 941 - 947. [Abstract] [Full Text]

				Q. M. Wang, R. Feinman, F. Kashanchi, J. M. Houghton, G. P. Studzinski, and L. E. Harrison Changes in E2F Binding after Phenylbutyrate-induced Differentiation of Caco-2 Colon Cancer Cells Clin. Cancer Res., July 1, 2000; 6(7): 2951 - 2958. [Abstract] [Full Text]

				Y. Huang, C. M. Horvath, and S. Waxman Regrowth of 5-Fluorouracil-treated Human Colon Cancer Cells Is Prevented by the Combination of Interferon {{gamma}}, Indomethacin, and Phenylbutyrate Cancer Res., June 1, 2000; 60(12): 3200 - 3206. [Abstract] [Full Text]

				T.-H. Chang and E. Szabo Induction of Differentiation and Apoptosis by Ligands of Peroxisome Proliferator-activated Receptor {{gamma}} in Non-Small Cell Lung Cancer Cancer Res., February 1, 2000; 60(4): 1129 - 1138. [Abstract] [Full Text]

				T. E. Witzig, M. Timm, M. Stenson, P. A. Svingen, and S. H. Kaufmann Induction of Apoptosis in Malignant B Cells by Phenylbutyrate or Phenylacetate in Combination with Chemotherapeutic Agents Clin. Cancer Res., February 1, 2000; 6(2): 681 - 692. [Abstract] [Full Text]